China Resources Controls Sanjiu Medical & Pharmaceutical
This article was originally published in PharmAsia News
New Sanjiu has become the majority shareholder after gaining 71.35 percent stake of Sanjiu Medical & Pharmaceutical. New Sanjiu, set up as a consolidated corporation held by Sanjiu Enterprise Group, has been undergoing restructuring since last July. China Resources Enterprise's subsidiary CR Medications Group raised 4 billion yuan ($572 million) to acquire Sanjiu Enterprise Group, effectively making CR Enterprise, which is aggressively pursuing the health business, the real controlling stakeholder of New Sanjiu. Sanjiu Medical, a key local pharmaceutical enterprise, has been in the doldrums for years due to poor strategizing of main shareholder Sanjiu Enterprise. Analysts expect the current equity transfer to boost the drug firm's future development. (Click here for more - Chinese language)
You may also be interested in...
In the only device-related warning letter released by the US FDA this week, Avazo Healthcare was selling two COVID-19 antigen tests without approval, clearance or authorization from the agency.
A sharp decline in the number of in-person facility inspections has forced the FDA to consider creative techniques for remotely evaluating manufacturer compliance during the COVID-19 pandemic. This and other stories topped our list of most-read Medtech Insight articles in November.
A package of health proposals intended to build up the EU’s resilience to health threats while strengthening the competitiveness of Europe’s pharmaceutical industry and ensuring access to affordable drugs takes a major step through the legislative process this week.